S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: World markets are lower after China unveils 5% economic growth target for 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: World markets are lower after China unveils 5% economic growth target for 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: World markets are lower after China unveils 5% economic growth target for 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: World markets are lower after China unveils 5% economic growth target for 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities

Innovate Biopharmaceuticals (INNT) Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.

INNT vs. NBRV, NOVN, NOVNQ, GNCAQ, GNCA, HTGMQ, VIVE, IGNY, AHPI, and VRAYQ

Should you be buying Innovate Biopharmaceuticals stock or one of its competitors? The main competitors of Innovate Biopharmaceuticals include Nabriva Therapeutics (NBRV), Novan (NOVN), NVN Liquidation (NOVNQ), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), HTG Molecular Diagnostics (HTGMQ), Viveve Medical (VIVE), Ignyte Acquisition (IGNY), Allied Healthcare Products (AHPI), and ViewRay (VRAYQ). These companies are all part of the "medical" sector.

Innovate Biopharmaceuticals vs.

Innovate Biopharmaceuticals (NASDAQ:INNT) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innovate Biopharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Nabriva Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Nabriva Therapeutics received 190 more outperform votes than Innovate Biopharmaceuticals when rated by MarketBeat users. However, 65.48% of users gave Innovate Biopharmaceuticals an outperform vote while only 59.10% of users gave Nabriva Therapeutics an outperform vote.

CompanyUnderperformOutperform
Innovate BiopharmaceuticalsOutperform Votes
203
65.48%
Underperform Votes
107
34.52%
Nabriva TherapeuticsOutperform Votes
393
59.10%
Underperform Votes
272
40.90%

Innovate Biopharmaceuticals has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Innovate Biopharmaceuticals' return on equity of 0.00% beat Nabriva Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Innovate BiopharmaceuticalsN/A N/A -234.42%
Nabriva Therapeutics -148.11%-365.53%-135.81%

In the previous week, Innovate Biopharmaceuticals had 5 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 6 mentions for Innovate Biopharmaceuticals and 1 mentions for Nabriva Therapeutics. Innovate Biopharmaceuticals' average media sentiment score of 0.00 equaled Nabriva Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Innovate Biopharmaceuticals
2 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Nabriva Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

5.9% of Innovate Biopharmaceuticals shares are owned by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are owned by institutional investors. 7.9% of Innovate Biopharmaceuticals shares are owned by insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Innovate Biopharmaceuticals has higher earnings, but lower revenue than Nabriva Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Innovate BiopharmaceuticalsN/AN/A-$27.05MN/AN/A
Nabriva Therapeutics$35.59M0.00-$57.19M-$19.200.00

Innovate Biopharmaceuticals has a beta of -0.39, indicating that its stock price is 139% less volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500.

Summary

Innovate Biopharmaceuticals beats Nabriva Therapeutics on 7 of the 12 factors compared between the two stocks.


Get Innovate Biopharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for INNT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INNT vs. The Competition

MetricInnovate BiopharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$8,000.00$6.69B$4.90B$7.55B
Dividend YieldN/A2.83%5.37%3.87%
P/E Ratio-1.7916.68265.1618.62
Price / SalesN/A224.282,950.7177.10
Price / CashN/A21.0832.6528.77
Price / BookN/A5.124.474.46
Net Income-$27.05M$152.61M$112.38M$212.48M

Innovate Biopharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NBRV
Nabriva Therapeutics
0 of 5 stars
$0.00
flat
N/AN/A$6,000.00$35.59M0.0039
NOVN
Novan
0.872 of 5 stars
$0.00
flat
$8.00
+888,788.9%
-99.9%$25,000.00$24.71M0.0090
NOVNQ
NVN Liquidation
0 of 5 stars
$0.00
flat
N/AN/A$25,000.00$23.68M0.0090
GNCAQ
Genocea Biosciences
0 of 5 stars
N/AN/AN/A$10,000.00$1.64M0.0074
GNCA
Genocea Biosciences
0 of 5 stars
N/AN/AN/A$6,000.00$1.91M0.0074
HTGMQ
HTG Molecular Diagnostics
0 of 5 stars
$0.01
flat
N/AN/A$11,000.00$6.37M0.0053
VIVE
Viveve Medical
0 of 5 stars
$0.00
flat
N/A-99.7%$2,000.00$6.83M0.0047
IGNY
Ignyte Acquisition
0 of 5 stars
$0.00
flat
N/A-99.8%$15,000.00N/A0.00N/A
AHPI
Allied Healthcare Products
0 of 5 stars
N/AN/AN/A$16,000.00$27.05M0.00189Analyst Report
VRAYQ
ViewRay
0 of 5 stars
N/AN/AN/A$20,000.00$102.21M0.00295

Related Companies and Tools

This page (NASDAQ:INNT) was last updated on 3/5/2024 by MarketBeat.com Staff